ABSTRACT
Introduction. Cannabis sativa has been cultivated for human use for about 5,000 years, and has likewise been used in the
treatment of epilepsy for thousands of years.
State of the art. Cannabidiol (CBD), which was isolated from cannabis sativa in 1940, has an anti-seizure effect and no psychoactive activity. Its effectiveness in reducing various types of seizures has been proven in animal seizure and epilepsy models.
Recent randomised, placebo-controlled trials have confirmed its effectiveness in patients with drug-resistant epilepsy.
Clinical implications. The aim of this position paper was to present the specific mechanism of CBD’s anti-seizure action and
current indications for CBD’s use in epilepsy. The only cannabis-derived drug that has successfully passed clinical trials and has
obtained United States Food and Drug Administration and European Medicines Agency approval for epilepsy is Epidiolex®. This
paper presents the outcomes of the completed clinical trials with the use of this drug.
Future directions. CBD may be an effective drug in drug-resistant epilepsy, particularly in Dravet Syndrome, Lennox-Gastaut Syndrome and seizures associated with tuberous sclerosis complex. Additional randomised, placebo-controlled studies with CBD are needed
